Good MorningEquities started Wednesday on solid footing rising more than 1.0% ahead of the FOMC meeting. The weaker-than-expected CPI gave the market some hope the Fed would give some relief and those hopes were dashed. While the Fed hiked rates by only 50 basis points the new statement indicated the peak of interest rates will likely be over 5.0% and remain at that level into 2023. This news caused the market to reverse course and the S&P 500 shed 0.60% at the close of the session.
The next hurdle for the market is the PCE price index which comes out next Friday. If the index confirms a downtrend in the pace of inflation it could send the market soaring and usher in the Santa Claus Rally. If not, the market could be in for a rough holiday as traders and investors begin to position for what could be a very bad year for stocks. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Energy | |
Enterprise Products Partners (NYSE: EPD) has recently been on a wild ride. It has gone thru some stunning peaks and troughs and ended up 7.82% year to date. As a result, investors might wonder if its current stock price represents a good entry for buying shares.
So let's examine the bull and... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Retail/Wholesale | |
Latin American e-commerce specialist MercadoLibre Inc. (NASDAQ: MELI) has only trended lower in 2022, and a new partnership could boost the stock.
Earlier this month, the chief financial officer of the Argentina-based company told Reuters that MercadoLibre would begin processing business payments... Read the Full Story |
|
Medical | |
U.S. mid-cap stocks are on pace to outperform their large-cap peers for the second straight year. The S&P 400 is down 13% year-to-date, a roughly 400 basis points edge over the S&P 500.
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Companies are... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Auto/Tires/Trucks | |
Updated - December 14, 2022– via InvestorWire – Mullen Automotive, Inc., an emerging electric vehicle (“EV”) manufacturer, announces today that it has entered into a definitive agreement with Loop Global Inc. ("Loop"), a full-service EV charging solution provider, to build ... Read the Full Story |
|
Transportation | |
REV Group (NYSE: REVG) has been struggling with supply chain issues and economic woe just like everybody else but now the stock is ready to make a major reversal. The company’s Q4 results and guidance for the year were better than expected and supported by the company’s diverse operati... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Technology | |
After a brutal year in the semiconductor space, things are starting to look up as we round the corner into 2023. Two of the better-known names to emerge as leaders in recent years, NVIDIA Corporation (NASDAQ: NVDA) and Advanced Micro Devices, Inc. (NASDAQ: AMD) have both seen their shares rally th... Read the Full Story |
|
Markets | |
Biotech stocks are often among the market’s most volatile, and Harpoon Therapeutics Inc. (NASDAQ: HARP) offers a perfect example of that.
The stock rocketed to an eight-month high Monday, advancing as much as 191% intraday before settling down to a gain of 22.61%. Shares closed at $1.41 Mon... Read the Full Story |
|
Basic Materials | |
Queen’s legendary 1977 rock anthem “We Are the Champions” was once deemed by scientists to be the catchiest song in popular music history. To this day, it is often heard in crowning moments at sports stadiums and in upbeat TV advertisements.
In the investment world, Freddy Mercu... Read the Full Story |
|
Medical | |
DexCom, Inc. (NASDAQ: DXCM) is a continuous glucose monitoring (CGM) company. In early December, they received approval from the United States Food and Drug Administration (FDA) for their new monitor, the G7. This device assists patients with Type 1 and Type 2 diabetes and gestational diabetes. Fu... Read the Full Story |
|
Retail/Wholesale | |
Premium retail department store chain Nordstrom, Inc. (NYSE: JWN) stock has fallen (-27%) in 2022. It’s recent earnings beat was overshadowed by falling YoY metrics. The sell-off was accelerated after bearish comments were made by CEO Erik Nordstrom at the Morgan Stanley Consumer & Retai... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. | | View Today's Stock Pick |
|
